4th Upper Egypt Pediatric Hematology and Oncology Conference 2025

In regions where access, resources, and early diagnosis can determine outcomes for children with life-threatening blood disorders and cancers, scientific dialogue is not optional—it is essential. The 4th Upper Egypt Pediatric Hematology and Oncology Conference (UEPHOA 2025) stood as a powerful platform where evidence-based medicine, regional experience, and global expertise converged to reshape pediatric hematology and oncology practice across Egypt and the Middle East.

Held on 18-19 December 2025 and welcoming +200 physical healthcare professionals, the conference delivered an intensive, clinically driven program accredited for 13.25 Category 1 CME hours by the American Association of Continuing Medical Education®, reinforcing its international scientific credibility and educational rigor.

A Scientifically Rich Program Addressing Real-World Pediatric Challenges

The UEPHOA 2025 scientific agenda was carefully structured to reflect the most pressing conditions in pediatric hematology and oncology, with a strong focus on diseases prevalent in the region and emerging global standards of care.

Redefining the Management of Hemoglobinopathies

The opening sessions set a strong clinical tone, beginning with a high-level panel on new horizons in sickle cell disease management, highlighting Arab countries’ experiences and region-specific treatment challenges. This was followed by in-depth discussions on thalassemia, including the growing role of digital health technologies in patient data management an area increasingly critical for long-term disease monitoring and outcomes.

Bleeding Disorders: From Early Recognition to Surgical Optimization

A major strength of the program was its deep dive into inherited and rare bleeding disorders. Expert-led sessions addressed:

• A major strength of the program was its deep dive into inherited and rare bleeding disorders. Expert-led sessions addressed:

• Practical approaches to Von Willebrand disease diagnosis and management
• Advances in Hemophilia B prophylaxis
• Surgical optimization strategies for patients with complex hematological conditions

These sessions moved beyond theory, offering clinicians actionable frameworks applicable in daily practice.

Immunology, Rare Diseases, and Precision Care

The conference further expanded its scope to include:

• Primary immunodeficiency disorders and the transformative role of IVIG
• Updated management strategies for paroxysmal nocturnal hemoglobinuria (PNH)
• Latest evidence in pediatric immune thrombocytopenia
• Comprehensive coverage of hereditary angioedema, including breakthrough biologic therapies

This breadth reflected the evolving intersection between hematology, immunology, and targeted therapeutics.

Multidisciplinary Oncology & Advanced Therapies

On Day Two, the scientific focus extended to bone marrow transplantation, emphasizing cross-talk between hematology, oncology, immunology, and laboratory medicine—an essential model for modern pediatric cancer care. Additional sessions tackled rare pediatric anemias, reinforcing the importance of early diagnosis, multidisciplinary handling, and regional referral pathways.

Throughout the program, the presence of international and regional faculty ensured that discussions were anchored in both global guidelines and local realities, bridging the gap between evidence and implementation.

CME Accreditation: Elevating Educational Impact

Accreditation by the American Association of Continuing Medical Education® for 13.25 Category 1 credit hours underscored the conference’s adherence to international educational standards. This recognition positioned UEPHOA 2025 not merely as a regional meeting, but as a globally aligned medical education activity with measurable professional value for attendees.

“This conference was designed to foster meaningful scientific exchange and translate knowledge into better care for children with hematological and oncological disorders. By bringing together experts from different disciplines and regions, we aim to build sustainable improvements in pediatric practice across Upper Egypt and beyond”, Prof. Hamdy Ghazaly, Conference President

This vision was clearly reflected in the program’s structure, speaker selection, and emphasis on practical, patient-centered outcomes.

Why UEPHOA 2025 Matters

Beyond sessions and CME hours, the 4th Upper Egypt Pediatric Hematology and Oncology Conference reinforced a critical message: advancing pediatric care requires regional ownership of global knowledge. By addressing diseases with high local prevalence, empowering multidisciplinary collaboration, and maintaining international scientific standards, UEPHOA 2025 played a vital role in shaping the future of pediatric hematology and oncology practice in Egypt and the wider region.

Professional Conference Management by ICOM Group

The successful delivery of the 4th Upper Egypt Pediatric Hematology and Oncology Conference 2025 reflects ICOM Group’s proven expertise in managing high-level medical and scientific conferences. From end-to-end planning and faculty coordination to on-site operations and CME compliance, ICOM Group ensured a seamless experience that allowed scientific dialogue to remain the central focus. Through structured execution, attention to detail, and alignment with international accreditation standards, ICOM Group continues to support the advancement of medical education and the delivery of impactful healthcare conferences across Egypt and the region.